Robbins Geller Rudman & Dowd LLP Announces
Amended Class Period for Class Action Suit Filed
Against Pfizer Inc.
May 14, 2010 06:45 PM Eastern Daylight Time
SAN DIEGO--(EON: Enhanced Online News)--Robbins Geller Rudman & Dowd LLP (“Robbins Geller”)
(http://www.rgrdlaw.com/cases/pfizerinc/) today announced that an amended class action complaint will be filed in
the United States District Court for the Southern District of New York. The amended complaint will be on behalf of
purchasers of Pfizer Inc. (“Pfizer”) (NYSE:PFE) publicly traded securities during the period between January 19,
2006 and January 23, 2009 (the “Class Period”).
If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from May 11, 2010. If you wish
to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s
counsel, Darren Robbins of Robbins Geller at 800/449-4900 or 619/231-1058, or via e-mail at email@example.com.
If you are a member of this class, you can view a copy of the existing complaint as filed or join this class action online
at http://www.rgrdlaw.com/cases/pfizerinc/. Any member of the putative class may move the Court to serve as lead
plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
The amended complaint will charge Pfizer and certain of its officers and directors with violations of the Securities
Exchange Act of 1934. Pfizer is a pharmaceutical company engaged in the discovery, development, manufacture,
and marketing of prescription medicines for humans and animals worldwide.
The amended complaint will allege that during the Class Period, defendants misled investors by failing to disclose that
they were engaged in an ongoing course of conduct designed to illegally promote the sale of Pfizer drugs, including
Bextra, Geodon, Zyvox and Lyrica. By such conduct, Pfizer caused hundreds of millions of dollars in false or
fraudulent claims to be submitted to several federal healthcare programs, thus exposing the Company to untold legal
On January 26, 2009, Pfizer announced that it was paying $2.3 billion to resolve several ongoing investigations.
These investigations included the improper promotion of and kickbacks involving Bextra, Geodon, Zyvox and
Lyrica. After the cost of resolving these investigations became public, the price of Pfizer common stock declined
from $17.45 at the previous trading day’s close to $15.65 on January 26, 2009.
Plaintiff seeks to recover damages on behalf of all purchasers of Pfizer publicly traded securities during the Class
Period (the “Class”). The plaintiff is represented by Robbins Geller, which has expertise in prosecuting investor class
actions and extensive experience in actions involving financial fraud.
Robbins Geller, a 180-lawyer firm with offices in San Diego, San Francisco, New York, Boca Raton, Washington,
D.C., Philadelphia and Atlanta, is active in major litigations pending in federal and state courts throughout the United
States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and
companies, as well as victims of human rights violations. The Robbins Geller Web site (http://www.rgrdlaw.com) has
more information about the firm.
Robbins Geller Rudman & Dowd LLP
Darren Robbins, 800-449-4900 or 619-231-1058